Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome

AIDS Reader

Volumn 17, Issue 6, 2007, Pages

  Brim, Nancy M ^a   Cu Uvin, Susan ^b,c   Hu, Susie L ^b   O'Bell, John W ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c MIRIAM HOSPITAL   (United States)

Author keywords

Fanconi syndrome; HIV AIDS; Osteopenia; Osteoporosis; Phosphorus balance; Tenofovir; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; COCAINE; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHORUS; TENOFOVIR; VITAMIN D;

ADULT; ARTICLE; BONE DISEASE; CASE REPORT; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATIENT MONITORING; PELVIS FRACTURE; PHOSPHATE METABOLISM; RIB FRACTURE; TREATMENT PLANNING; VITAMIN D METABOLISM;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES; FANCONI SYNDROME; FEMALE; FEMORAL NECK FRACTURES; HIV INFECTIONS; HUMANS; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 34250369259     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis. 2003;41:292-309.
2. Cihlar T, Burkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002;54:37-45.
3. Viread (tenofovir) [prescribing information]. Foster City, Calif: Gilead Sciences; March 2006. Available at: http://www.gileadhiv.com/pdf/VirendFPI.pdf. Accessed May 14, 2007.
4. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment - case report and review of literature. J Infect. 2005;51:e61-e65.
5. Parsonage MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. 2005;6:341-346.
6. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005;19:93-95.
7. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003;17:935-937.
8. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282-284.
9. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6:284-290.
10. Izzedine H, Launay-Vacher V, Deray G. Antiviral, drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804-817.
11. Williams J, Chadwick DR. Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia. J Infect. 2006;52:e107-e108.
12. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-1073.
13. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res. 2004;19:714-721.
14. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-1333.
15. Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinayir/ritonavir. Pediatr Nephrol. 2006;21:1034-1036.
16. Quimby D, Brito MO. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Reader. 2005;15:357-364.
17. Breton G, Alexandre M, Duval X, et al. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis. 2004;36:527-528.
18. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS. 2004;18:351-352.
19. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24:415-418.
20. Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect. 2003;47:262-263.
21. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174-e176.
22. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283-290.
23. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18:960-963.
24. Hansen AB, Mathiesen S, Gerstoft J. Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand J Infect Dis. 2004;36:389-392.
25. Krummel T, Parvez-Braun L, Frantzen L, et al. Tenofovir-induced acute renal failure in an HIV patient with normal renal function. Nephrol Dial Transplant. 2005;20:473-474.
26. Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:e41-e43.
27. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.
28. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703-709.
29. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients. Is it the disease or is it treatment. AIDS. 2001;15:807-808.
30. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS. 2001;15:1731-1733.
31. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490.
32. Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS. 2004;18:475-483.
33. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV + postmenopausal women. Osteoporos Int. 2005;16:1345-1352.
34. Lawal A, Engelson ES, Wang J, et al. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS. 2001;15:278-280.
35. Brown TT, McComsey GA. Osteopenia and osteoporosis in patients with HIV: a review of the current concepts. Curr Infect Dis Rep. 2006;8:162-170.
36. Mellert W, Kleinschmidt A, Schmidt J, et al. Infection of human fibroblasts and osteoblast-like cells with HIV-I. AIDS. 1440;4:527-535.
37. Salzman NP, Psallidopoulos M, Prewett AB, O'Leary R. Detection of HIV in bone allografts prepared from AIDS autopsy tissue. Clin Orthop Relat Res. 1993;292:384-390.
38. Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282-290.
39. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-309.
40. Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42:1014-1020.
41. Annapoorna N, Rao GV, Reddy NS, et al. An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci. 2004;1:152-164.
42. Garcia Aparicio AM, Munoz Fernandez S, Gonzalez I, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006;25:537-539. Epub 2005 Oct 6.
43. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39-48.
44. Fernandez-Rivera J, Garcia R, Lozano F, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials. 2003;4:337-346.
45. Bongiovanni M, Fausto A, Cicconi P, et al. Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr. 2005;40:503-504.
46. Haug CJ, Aukrust P, Hang E, et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83:3832-3838.
47. Heaney RP, Recker RR, Saville PD. Menopausal changes in bone remodeling. J Lab Clin Med. 1978;92:964-970.
48. Mazzuoli GF, D'Erasmo E, Minisola S, et al. Pathogenetic aspects of involutional osteoporosis. Clin Rheumatol. 1989;8:22-29.
49. Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis. 2003;37(suppl 2):S132-S136.
50. Pedrazzoni M, Vescovi PP, Maninetti L, et al. Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol (Copenh). 1993;129:42-45.
51. Schoenbaum EE, Hartel D, Lo Y, et al. HIV Infection, drug use, and onset of natural menopause. Clin Infect Dis. 2005;41:1517-1524.
52. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
53. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641-648.
54. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized double blind study. AIDS. 2002;16:1257-1263.
55. US Food and Drug Administration. FDA report: background package for NDA 21-356: Viread 2001. Available at: http://www.fda.gov/cder/foi/nda/2001/21- 336_Viread_biophrmr.pdf. Accessed May 10, 2007.
56. Flaherty J, Kearney B, Wolf J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir or lopinavir/ritonavir. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires. Abstract 336. Available at: http://www.aegis.org/conferences/IASHIVPT/2001/336.html. Accessed May 7, 2007.
57. Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999;56:383-389.
58. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther. 2001;299:567-574.
59. Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf). 1995;43:479-490.
60. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269-273.
61. Bonnardeux A, Bichet DG. Inherited disorders of the renal tubule. In: Brenner BM, ed. Brenner & Rector's The Kidney. 7th ed. Philadelphia: Saunders; 2003:1697-1741.
62. Brewer ED, Tsai HC, Szeto KS, et al. Maleic acid-induced conversion of 25-(OH)D3 to 1,25-(OH)2D3: implications for Fanconi's syndrome. Kidney Int. 1977;12:244-252.
63. Khoury S, Tucci JR. Fanconi syndrome and osteomalacia without hyperparathyroidism. R I Med J. 1986;69:33-36.
64. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19:2031-2033.
65. Ramayo E, Gonzalez-Moreno MP, Macias J, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2005;21:915-921.
66. Tsai CC, Follis KF, Beck TW, et al. Effects of (R)-9-(2- phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses. 1997;13:707-712.
67. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
68. Castillo AB, Tarantal AF, Watnik MR, Martin RB. Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res. 2002;20:1185-1189.
69. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469-1487.
70. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a doubleblind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743-746.
71. Badiou S, De Boever CM, Terrier N, et al. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect. 2006;52:335-338. Epub 2005 Sept 19.
72. Day SL, Leake Date HA, Bannister A, et al. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Syndr. 2005;38:301-304.
73. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718.
74. Reynes J, Peyriere H, Merle de Boever C, Le Moing V. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy. 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 717. Available at: http://www.retroconference.org/ 2003/cd/Abstract/717.htm. Accessed May 10, 2007.
75. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.
76. Izzedine H, Launay-Vacher V, Jullien V, et al. Pharmaokinetics of tenofovir in haemodialysis. Nephrol Dial Transplant. 2003;18:1931-1933.
77. Kearney BP, Yale K, Hayashi S, et al. Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment, 6th International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, UK. Abstract P4.
78. Negredo E, Martinez-Lopez E, Paredes R, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS. 2005;19:343-345.
79. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials. 2004;5:269-277.
80. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
81. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a doubleblind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743-746.
82. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.